The cornerstone investors in the deal are
Alibaba-backed Taobao China (US$50m),
Henderson Land chairman Lee Shau Kee-backed
Successful Lotus (US$38m), Overseas Chinese
Town-owned City Legend International
(US$151m) and City Developments-owned
Educado Company (US$30m).
Books opened last week and close on July
- Shares list on July 20.
The proceeds will be used to further
develop the real estate big data system and
expand geographical coverage in the primary
market and the brokerage network of the real
estate agency services. The remainder will be
used for staff training, marketing or other
general corporate purposes.
4HEûCOMPANYûPOSTEDûAûûPROlTûANDû
total comprehensive income of Rmb765.3m
(US$115m) on revenues of Rmb4.6bn.
CICC and Credit Suisse are joint sponsors and
Citigroup is joint bookrunner for the deal.
HUJIANG FILES FOR HONG KONG IPOHUJIANG EDUCATION AND TECHNOLOGY (SHANGHAI)
CORPORATION, an online education provider,
has applied for a Hong Kong IPO to raise up
to US$500m, a person close to the deal
said.
CMB International and Haitong are joint
SPONSORSûOFûTHEûmOAT
Huijiang operates nearly 2,000 proprietary
online courses and runs the CCtalk website.
Established in 2016, CCtalk had 2.3 million
monthly active users in 2017, of which
255,298 paid to use the service.
The company posted a loss of Rmb537m
(US$80m) in 2017, up from a loss of Rmb421m
INû ûACCORDINGûTOûAûREGULATORYûlLING
Six shareholders, Cao Jian, Fu Cairui, Yu
Jie, Tang Xiaozhe, An Jialiang and Jiang
Shaojun, control the company through
Hujie Investment, Hujiang Investment, Huji
Investment, Shanghai Chengta, Huyuan
Investment and Hunian Investment.ASCLETIS SEEKS LISTING APPROVALASCLETIS PHARMA has sought listing approval
from the Stock Exchange of Hong Kong,
BECOMINGûTHEûlRSTûBIOTECHûCOMPANYûTOûlLEû
under new IPO rules.The company plans to raise about
US$500m from the IPO in the second half of
the year, IFR reported earlier.
3INCEû!PRILû ûBIOTECHûlRMSûWITHûNOû
PROlTSûORûREVENUEûCANûLISTûINû(ONGû+ONGû
People close to the deal had previously told
IFR the valuation of Ascletis could reach
US$2bn–$3bn at the time of listing.
Founded in 2013, Hangzhou-based
Ascletis manufactures anti-viral, cancer and
liver-disease drugs.
The company posted revenue of Rmb9m
(US$1.4m) in 2017, down 85% from a year
earlier.
China Merchants Securities, Goldman Sachs
and Morgan Stanley are joint sponsors for the
IPO.JIUJIANG PRICES IN LOWER HALFThe Hong Kong IPO of BANK OF JIUJIANG is set
to raise HK$3.8bn (US$487m) after being
priced at HK$10.6 per share, in the lower
half of the HK$10.48–$10.96 indicative
range, a person with knowledge of the
transaction has said.EQUITIES ASIA-PACIFICASIA-PACIFIC EQUITIES
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 Morgan Stanley 50 11,477.08 9.1
2 Citigroup 48 8,965.74 7.1
3 Goldman Sachs 44 8,738.71 6.9
4 UBS 33 6,428.30 5.1
5 BAML 13 5,770.58 4.6
6 CICC 10 5,627.00 4.5
7 Citic 30 4,729.62 3.7
8 Credit Suisse 26 4,500.29 3.6
9 JP Morgan 26 4,158.88 3.3
10 Nomura 48 2,840.49 2.2
Total 1,268 126,284.42
Including all domestic and international deals and rights issues
Source: Thomson Reuters SDC code: C4a1
ASIA-PACIFIC EQUITIES (EX-JAPAN)
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 Morgan Stanley 34 9,545.08 8.6
2 Goldman Sachs 43 8,686.14 7.8
3 Citigroup 44 8,559.76 7.7
4 UBS 31 6,187.61 5.6
5 CICC 10 5,627.00 5.0
6 BAML 10 5,176.43 4.6
7 Citic 30 4,729.62 4.2
8 Credit Suisse 25 4,327.16 3.9
9 JP Morgan 22 3,388.94 3.0
10 China Securities Co 17 2,788.09 2.5
Total 1,151 111,464.75
Including all domestic and international deals and rights issuesSource: Thomson Reuters SDC code: C4a2ASIA-PACIFIC IPOs
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 CICC 8 5,084.42 12.1
2 Citic 16 2,049.16 4.9
3 Morgan Stanley 17 2,039.91 4.9
4 Goldman Sachs 10 1,783.31 4.2
5 Credit Suisse 11 1,559.87 3.7
6 BAML 6 1,421.00 3.4
7 Huatai Securities 10 1,415.12 3.4
8 Guotai Junan Securities 10 1,157.07 2.8
9 JP Morgan 11 1,050.64 2.5
10 China Securities Co 8 1,015.10 2.4
Total 450 41,999.74
Including all domestic and international deals Proportional creditSource: Thomson Reuters SDC code: C04a6ASIA-PACIFIC SECONDARY OFFERINGS
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 Morgan Stanley 33 9,437.17 11.2
2 Citigroup 39 8,054.12 9.6
3 Goldman Sachs 34 6,955.40 8.3
4 UBS 27 5,851.31 6.9
5 BAML 7 4,349.59 5.2
6 JP Morgan 15 3,108.24 3.7
7 Credit Suisse 15 2,940.42 3.5
8 Citic 14 2,680.46 3.2
9 Sumitomo Mitsui Finl 26 2,233.06 2.6
10 Mizuho 17 1,950.43 2.3
Total 818 84,284.69
Including all domestic and international deals and rights issues
Proportional credit
Source: Thomson Reuters SDC code: C04a6
ASIA-PACIFIC IPOs (EXCLUDING JAPAN)
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 CICC 8 5,084.42 13.1
2 Citic 16 2,049.16 5.3
3 Goldman Sachs 10 1,783.31 4.6
4 Credit Suisse 11 1,559.87 4.0
5 Morgan Stanley 12 1,473.38 3.8
6 Huatai Securities 10 1,415.12 3.7
7 BAML 5 1,312.13 3.4
8 Guotai Junan Securities 10 1,157.07 3.0
9 China Securities 8 1,015.10 2.6
10 China Merchants Secs 8 964.16 2.5
Total 408 38,725.64
Including all domestic and international deals
Proportional creditSource: Thomson Reuters SDC code: C04a4ASIA-PACIFIC SECONDARY OFFERINGS
(EXCLUDING JAPAN)
BOOKRUNNERS: 1/1/2018–30/6/2018
Managing No of Total Share
bank or group issues US$(m) (%)
1 Morgan Stanley 22 8,071.70 11.1
2 Citigroup 35 7,648.14 10.5
3 Goldman Sachs 33 6,902.83 9.5
4 UBS 25 5,610.62 7.7
5 BAML 5 3,864.30 5.3
6 Credit Suisse 14 2,767.29 3.8
7 Citic 14 2,680.46 3.7
8 JP Morgan 12 2,447.17 3.4
9 China Securities Co 9 1,772.99 2.4
10 Macquarie Group 12 1,705.47 2.3
Total 743 72,739.11
Including all domestic and international deals and rights issues
Proportional credit
Source: Thomson Reuters SDC code: C04a5r